OrthoLogic promotion of bone growth stimulator for unapproved indications cited by FDA.
This article was originally published in The Gray Sheet
Executive Summary
ORTHOLOGIC BONE GROWTH STIMULATOR PROMOTIONAL CLAIMS, DEVICE MODIFICATIONS require submission of a premarket approval application supplement, FDA says in a May 31 warning letter to the firm. FDA says the company has promoted the OrthoLogic 1000 for treatment of fracture types beyond those approved by the agency and has made modifications to the device that require premarket approval.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.